The top 20 bestselling drugs of 2020 generated 64% of their global revenue from the United States, according to Axios. Solt DB's dataset shows not much has changed in the last three years.

• The top 5 bestselling drugs generated 70.7% ($55.010 billion) of revenue from the United States in 2023.
• The top 10 bestselling drugs leaned on American patients for 64.6% ($84.398 billion) of global revenue in 2023.
• The top 20 bestselling drugs settled at 61.6% ($126.645 billion) in 2023.
• There were 145 blockbusters that reported geographic revenue splits, or 144 excluding Paxlovid (which had negative revenue in the United States in 2023). Among that group, the United States was responsible for 59.3% ($298.233 billion) of total revenue.
• When the list of 144 blockbusters with available data is further truncated to exclude the three coronavirus vaccines (including Johnson & Johnson's unbranded product), which generate no more than 26% of revenue from the United States, the world's blockbuster drugs generated 60.8% of revenue from American patients in 2023.